A phase II, presurgical study to evaluate molecular alterations that occur in human breast cancer tissue and normal skin after short term exposure to ZD1839 (IRESSA) and to correlate these alterations with pharmacokinetic parameters.

Trial Profile

A phase II, presurgical study to evaluate molecular alterations that occur in human breast cancer tissue and normal skin after short term exposure to ZD1839 (IRESSA) and to correlate these alterations with pharmacokinetic parameters.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Early breast cancer
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 May 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12607000013460), additional centre, investigator and additional identifier added.
    • 01 May 2009 Actual initiation date (Feb 2005) added as reported by ClinicalTrials.gov.
    • 05 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top